Media stories about Nymox Pharmaceutical Corporation (NASDAQ:NYMX) have trended somewhat positive recently, Accern reports. The research firm ranks the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Nymox Pharmaceutical Corporation earned a daily sentiment score of 0.11 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 44.9133494437159 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Separately, ValuEngine lowered shares of Nymox Pharmaceutical Corporation from a “hold” rating to a “sell” rating in a research note on Monday, July 24th.
Shares of Nymox Pharmaceutical Corporation (NASDAQ NYMX) opened at 3.69 on Friday. The company’s market capitalization is $193.23 million. The stock has a 50 day moving average of $3.75 and a 200-day moving average of $3.84. Nymox Pharmaceutical Corporation has a 52 week low of $2.67 and a 52 week high of $5.10.
In other news, Director James George Robinson acquired 8,500 shares of Nymox Pharmaceutical Corporation stock in a transaction on Wednesday, June 28th. The stock was bought at an average price of $4.09 per share, for a total transaction of $34,765.00. Following the completion of the purchase, the director now owns 3,040,050 shares in the company, valued at $12,433,804.50. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last quarter, insiders acquired 152,500 shares of company stock valued at $583,370. 54.00% of the stock is owned by company insiders.
COPYRIGHT VIOLATION NOTICE: This piece of content was posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://stocknewstimes.com/2017/08/26/nymox-pharmaceutical-corporation-nymx-receiving-somewhat-positive-press-coverage-report-finds.html.
Nymox Pharmaceutical Corporation Company Profile
Nymox Pharmaceutical Corporation, formerly Corporation Pharmaceutique Nymox, is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products.
Receive News & Ratings for Nymox Pharmaceutical Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
